Related Experiment Video

Updated: May 23, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Improving treatment of HER2-positive cancers: opportunities and challenges

Howard M Stern1

  • 1Department of Research Pathology, Genentech Inc., South San Francisco, CA 94080-4990, USA. stern.howard@gene.com

Science Translational Medicine
|March 31, 2012
PubMed

Insights

HER2-positive cancers are driven by ERBB2 gene amplification. Current therapies like trastuzumab improve outcomes, but resistance necessitates new treatments. Future therapies show promise for better patient results.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • ERBB2 gene amplification drives proliferation in HER2-positive breast and gastric cancers.
  • Targeted therapies like trastuzumab and lapatinib have improved patient outcomes.
  • Challenges remain, including mechanisms of resistance to current treatments.

Purpose of the Study:

  • To review proposed mechanisms of action for HER2-targeted therapies.
  • To discuss mechanisms of resistance to HER2-targeted therapies.
  • To explore potential new therapeutic options for HER2-positive cancers.

Main Methods:

  • Literature review of proposed mechanisms of action.
  • Analysis of resistance pathways in HER2-positive cancers.
  • Evaluation of emerging therapeutic strategies.

Main Results:

  • HER2 overexpression is a key driver in specific cancers.
  • Trastuzumab and lapatinib offer clinical benefits but face resistance.
  • Understanding resistance mechanisms is crucial for developing novel therapies.

Conclusions:

  • New therapeutic approaches are under development for HER2-positive cancers.
  • These novel therapies aim to overcome existing treatment challenges.
  • Further advancements are expected to improve clinical outcomes for patients.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...